Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 6/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22828309 | 0.87 | MAPT (0.40) | TRPA1MAPTMMP2MMP9MDM2 | |
| SCHEMBL22828139 | 0.84 | HSD17B10 (0.37) | TRPA1MAPTMMP2MMP9MDM2 | |
| SCHEMBL22828318 | 0.79 | KMT2A (0.34) | MMP2MMP9MEN1KMT2AMAOB | |
| SCHEMBL22828315 | 0.73 | MMP2 (0.43) | MMP2MMP9MEN1KMT2A | |
| SCHEMBL22828311 | 0.73 | DRD2 (0.38) | MAPTMEN1KMT2AL3MBTL1MAPK1 | |
| SCHEMBL22828317 | 0.72 | ALDH1A1 (0.40) | MAPTMMP2MMP9MEN1KMT2A | |
| SCHEMBL22828312 | 0.72 | ALDH1A1 (0.54) | MAPTKMT2AALDH1A1 | |
| SCHEMBL22828319 | 0.70 | PTGS2 (0.40) | MDM2HSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL22828316 | 0.68 | TAAR1 (0.38) | MAPTHSD17B10MEN1KMT2AALDH1A1 | |
| SCHEMBL22828122 | 0.68 | CHRNB2 (0.44) | MDM2HSD17B10ALDH1A1L3MBTL1TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377420-B2 | Compositions and methods for making donor-acceptor azetines | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200399214-A1 | COMPOSITIONS AND METHODS FOR MAKING DONOR-ACCEPTOR AZETINES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377420-B2 | Compositions and methods for making donor-acceptor azetines | AZI2, AAAS, ZRANB2 | TRPA1 3890/4885MAPT 3602/4885MMP2 4601/4885 |
| US-20200399214-A1 | COMPOSITIONS AND METHODS FOR MAKING DONOR-ACCEPTOR AZETINES | AZI2, AAAS, ZRANB2 | TRPA1 3890/4885MAPT 3602/4885MMP2 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.